Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:5603 |
Name | T-cell acute lymphoblastic leukemia |
Definition | An acute lymphoblastic leukemia that is characterized by too many T-cell lymphoblasts found in the bone marrow and blood. |
Source | DiseaseOntology.org |
Alt Ids | DOID:715 DOID:5599 |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia acute lymphoblastic leukemia T-cell acute lymphoblastic leukemia |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
JAK3 M511I | Tofacitinib | T-cell acute lymphoblastic leukemia | sensitive | detail... |
JAK3 M511I | Ritlecitinib | T-cell acute lymphoblastic leukemia | sensitive | detail... |
JAK3 M511I | Selumetinib | T-cell acute lymphoblastic leukemia | sensitive | detail... |
JAK3 M511I | Dexamethasone + Tofacitinib | T-cell acute lymphoblastic leukemia | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02112916 | Phase III | Cyclophosphamide Vincristine Sulfate Ifosfamide Pegaspargase Methotrexate Cytarabine Mercaptopurine Thioguanine Leucovorin Daunorubicin Dexamethasone Bortezomib Etoposide Doxorubicin | Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma | Active, not recruiting | USA | NZL | CAN | AUS | 0 |
NCT02518113 | Phase Ib/II | Dexamethasone LY3039478 | A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL | Completed | USA | ITA | ISR | FRA | DEU | 0 |
NCT02535806 | Phase II | Vincristine Sulfate Bortezomib Pegaspargase Methotrexate Cytarabine Mitoxantrone Prednisone | Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults | Terminated | USA | 0 |
NCT02881086 | Phase III | Rituximab Doxorubicin Cytarabine Mercaptopurine Nelarabine Methotrexate Pegaspargase Cyclophosphamide Vindesine Vincristine Sulfate Daunorubicin Dexamethasone | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | Active, not recruiting | DEU | 0 |
NCT03081910 | Phase I | CD5 CAR-T cells Cyclophosphamide + Fludarabine | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) | Recruiting | USA | 0 |
NCT03328104 | Phase I | Cyclophosphamide + Etoposide + Everolimus + Nelarabine | Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma (ENCERT) | Completed | USA | 0 |
NCT03590171 | Phase II | Bortezomib | International Study for Treatment of High Risk Childhood Relapsed ALL 2010 | Recruiting | SWE | POL | NOR | NLD | ITA | ISR | GBR | FRA | FIN | DNK | CZE | BEL | AUT | AUS | 1 |
NCT03829540 | Phase I | CD4CAR | CD4CAR for CD4+ Leukemia and Lymphoma | Recruiting | USA | 0 |
NCT03957915 | Phase I | INA03 | Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia (INA03) | Recruiting | FRA | 0 |
NCT04128501 | Phase II | Azacitidine + Venetoclax | Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | Recruiting | USA | 0 |
NCT04307576 | Phase III | Imatinib Blinatumomab Inotuzumab ozogamicin | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | Recruiting | SWE | NOR | NLD | LTU | ISL | IRL | GBR | FRA | FIN | EST | DNK | DEU | BEL | 1 |
NCT04315324 | Phase II | OBI-3424 | Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) | Recruiting | USA | 0 |
NCT04502446 | Phase I | CTX130 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies | Active, not recruiting | USA | CAN | AUS | 0 |
NCT04681105 | Phase I | Acetaminophen + Dexamethasone + Diphenhydramine + Flotetuzumab + Ranitidine Dexamethasone + Diphenhydramine + Flotetuzumab + Ibuprofen + Ranitidine | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | Active, not recruiting | USA | 0 |
NCT04771572 | Phase I | LP-118 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Recruiting | USA | 0 |
NCT04972942 | Phase I | Daratumumab | Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma (ALLO-T-DART) | Recruiting | USA | 0 |
NCT04984356 | Phase Ib/II | WU-CART-007 | A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL | Completed | USA | NLD | FRA | AUS | 0 |
NCT05032183 | Phase Ib/II | Cytarabine + Filgrastim + Methotrexate + Rituximab + Tagraxofusp-erzs Cyclophosphamide + Dexamethasone + Mesna + Methotrexate + Rituximab + Tagraxofusp-erzs + Vincristine Sulfate Tagraxofusp-erzs | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Active, not recruiting | USA | 0 |
NCT05038644 | Phase I | XmAb18968 | XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia | Active, not recruiting | USA | 0 |
NCT05054465 | Phase Ib/II | Navitoclax + Venetoclax | A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL (ITALLI001) | Not yet recruiting | ISR | 0 |
NCT05268003 | Phase II | Ponatinib Venetoclax | A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia | Active, not recruiting | USA | 0 |
NCT05289687 | Phase II | Daratumumab and hyaluronidase-fihj | Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL | Recruiting | USA | 0 |
NCT05292664 | Phase I | Azacitidine + Cytarabine + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax Calaspargase pegol-mknl + Cytarabine + Dexamethasone + Dexrazoxane + Doxorubicin + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax + Vincristine Sulfate Azacitidine + Venetoclax | Venetoclax Basket Trial for High Risk Hematologic Malignancies | Recruiting | USA | 0 |
NCT05464836 | Phase II | CB-103 + Venetoclax | Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL | Terminated | USA | 0 |
NCT05581030 | Phase I | Calaspargase pegol-mknl + Cyclophosphamide + Dexamethasone + Doxorubicin + Rituximab + Vincristine Sulfate Cytarabine + Methotrexate Calaspargase pegol-mknl + Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate | CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | Recruiting | USA | 0 |
NCT05679895 | Phase I | CD1a CAR T cells | Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL (CARxALL) | Recruiting | ESP | 0 |
NCT05885464 | Phase Ib/II | BEAM-201 | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) | Recruiting | USA | 0 |
NCT06064903 | Phase Ib/II | Cyclophosphamide + Fludarabine CD7-CART01 cells | CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL (CD7-CAR01) | Recruiting | ITA | 0 |
NCT06207123 | Phase Ib/II | Dexamethasone + Methotrexate + Vincristine Sulfate LP-118 + Ponatinib | A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) | Recruiting | USA | 0 |
NCT06326463 | Phase I | CD70-CAR-T cells Cyclophosphamide + Fludarabine Mesna | CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies | Recruiting | USA | 0 |
NCT06390319 | Phase II | Cyclophosphamide + Cytarabine + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Vincristine Sulfate Bortezomib + Calaspargase pegol-mknl + Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Vincristine Sulfate Bortezomib + Calaspargase pegol-mknl + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Nelarabine + Vincristine Sulfate Calaspargase pegol-mknl + Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Nelarabine + Venetoclax + Vincristine Sulfate Calaspargase pegol-mknl + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Venetoclax + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Nelarabine + Vincristine Sulfate Thioguanine Calaspargase pegol-mknl + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Nelarabine + Vincristine Sulfate Calaspargase pegol-mknl + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Vincristine Sulfate | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) | Not yet recruiting | USA | 0 |
NCT06522373 | Phase I | TAK-169 | Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease | Withdrawn | 0 | |
NCT06561074 | Phase II | Calaspargase pegol-mknl + Decitabine + Venetoclax | A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) | Not yet recruiting | USA | 0 |